Herein,
we review POK/ZBTB protein function in lymphoid development, with particular emphasis on the role of LRF in GC B cells.”
“In the survival analysis context, when an intervention either reduces a harmful exposure or introduces a beneficial treatment, it seems useful to quantify the gain in survival attributable to the intervention as an alternative to the reduction in risk. To accomplish this we introduce two new concepts, the attributable survival and attributable survival time, and study their properties. Our analysis includes comparison with the attributable risk function as well as hazard-based alternatives. We also extend the setting to the case where the intervention takes place at discrete points in time, and may either eliminate exposure or introduce a beneficial VX-689 treatment in only a proportion of the available group. This generalization accommodates the more realistic situation where the treatment or exposure is dynamic. We apply these methods to assess the effect of introducing highly active antiretroviral therapy for the treatment of clinical AIDS at the population level. Copyright (C) 2009 John Wiley & Sons, Ltd.”
“Sorafenib induces early vascularity reduction in patients with hepatocellular carcinoma (HCC). We sought to identify differences in radiological assessment
approaches and to evaluate find more their usefulness for the prediction of the initial response to sorafenib.\n\nForty-eight patients with advanced HCC treated with sorafenib were evaluated by four-phase contrast-enhanced computed tomography. All target lesions were analyzed using the Response Evaluation Criteria in Solid Tumors (RECIST), the EASL criteria, and
modified RECIST (mRECIST).\n\nAt the initial evaluation at 4-6 weeks, rates of objective response (OR) (including both complete and partial responses), stable disease (SD), and progressive disease (PD) were 2, 71, and 27 %, respectively, according to RECIST; 15, 56, and 29 %, respectively, according to the EASL criteria; and 15, 58, and 27 %, respectively, according to mRECIST. Patients who achieved an OR according to the EASL criteria also achieved an OR according to mRECIST. Patients who achieved an OR according to the EASL criteria PFTα manufacturer or mRECIST had better predicted overall survival (OS) than did patients who achieved SD (p = 0.033 and 0.028, respectively). Patients with SD according to RECIST had different outcomes depending on the response according to enhancement criteria. Patients classified as responders (complete and partial) had better predicted OS than those classified as non-responders (those classified as SD and PD) (p = 0.048).\n\nThe enhancement criteria could be useful for prediction of the initial response to sorafenib in patients with HCC. Moreover, mRECIST appears to be simple and convenient.